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Brain metastases in osteosarcoma: incidence, clinical and neuroradiological 
findings and management options 
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Summary 
Brain metastasis  uncommon in osteosarcoma, but this may be changing with prolonged patient survival in 
the modern chemotherapy era. We present 5patients with brain metastases out of 39 with lung metastasis (13 %) 
in a total of 87 osteosarcoma p tients. 
The clinical manifestations of brain metastases were catastrophic: massive hemorrhage in 2 and status epilep- 
ticus in 3. Metastases were single or multiple, and some were osteoblastic. Surgical intervention i 2 cases result- 
ed in dramatic, though transient, clinical improvement. 
We advocate periodic neuroradiology screening in osteosarcoma p tients with lung metastases, for early de- 
tection of brain involvement. 
Introduction 
Osteosarcoma, one of the most common malignant 
bone tumors in children and adolescents, rarely 
metastasizes to the central nervous ystem. The pat- 
tern of dissemination of this neoplasm is usually 
hematogenous, with lungs and bone being the main 
targets [1- 8]. Thus, in a large series of patients with 
osteosarcoma, 90% of those who relapsed had lung 
metastases and approximately 50% had bone lesions 
[3]. Brain metastases were usually found only in au- 
topsy series or as a late, pre-terminal event [3, 5, 8]. 
The initiation of chemotherapy for osteosarcoma 
in the early 70's has altered the natural history of this 
disease [6-10]. While lung metastases would gener- 
ally appear within the first year, and the five-year 
survival was less than 20% in pre-chemotherapy 
days, current results are far superior, yielding sur- 
vival rates in excess of 60% [1, 2]. Moreover, the 
prolonged survival of patients has permitted the ap- 
pearance of new, significant argets for metastasis, 
such as the heart, abdomen and brain [7-10]. In the 
past year, we have observed the occurrence of brain 
metastases in several children and adolescents with 
osteosarcoma. This prompted a review of the records 
of all patients with this neoplasm seen and treated 
at our institution in the past 5 years. This report sum- 
marizes the incidence, clinical presentation, 
management, and outcome of these patients. 
Patients and methods 
Patients 
Consecutive untreated pediatrc patients with os- 
teosarcoma, admitted from 1980 to 1986 to the 
M. D. Anderson Hospital were evaluated. They were 
initially randomized to two preoperative chemother- 
apy regimens: high dose methotrexate with citrovo- 
rum factor (MTS-CF) and intra-arterial cis- 
diamminedichloroplatinum II (CDP). The initial 
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treatment was administered for 6 to 12 weeks, 
provided a response was achieved. Thereafter, a sur- 
gical procedure was performed. The extent of tumor 
destruction was then assessed by pathologic exami- 
nation of the surgical specimen. Patients responding 
to the preoperative treatment (over 60 % destruction) 
continued with the agent used preoperatively and 
with the addition of other agents (Fig. 1). Alterna- 
tively, if preoperative treatment was considered in- 
effective (tumor destruction' under 60%),, the 
preoperative agent was discarded. The total duration 
of postoperative adjuvant reatment was one year. 
Prior to the initiation and during the course of 
treatment, routine chest radiographs were obtained 
at monthly intervals and computerized tomography 
(CT) scans of the chest and bone scans at 6 monthly 
intervals. Other investigations were obtained as dic- 
tated by the clinical status. Finding of pulmonary 
metastases led to surgical consultation and, when 
feasible, resection of the metastases. In all cases, the 
diagnosis of osteosarcoma w s confirmed by patho- 
logic examination of the presenting tumor. Eighty 
seven patients were considered evaluable for review, 
including two admitted with pulmonary metastases. 
Results 
Table 1 illustrates the patient characteristics of this 
patient population. Comparison of age, sex, and 
time-to-pulmonary-metastasis revealed no differ- 
ence between the total patient population and those 
who developed brain metastases. All patients with 
brain metastases had developed pulmonary disease, 
some of which were resected. In all cases, the appear- 
ance of brain metastases was concurrent with, or 
subsequent to, occurrence of lung metastases. Ta- 
ble 2 illustrates the salient features of the 5 patients 
with brain metastases. The CT in 2 cases revealed a
hemorrhagic mass lesion (Fig. 2), surgically verified 
in I case. Dense calcification and/or osteoid was 
seen in the lesions of 1 patient (Fig. 3), which was 
confirmed pathologically. The CT scans of 2 pa- 
tients were performed at outside hospitals and were 
unavailable for review by us, but reportedly were 
consistent with brain metastasis inboth cases (no au- 
topsies were done). At the time of diagnosis of 
metastatic brain disease, 3of the 5 patients presented 
with seizures, progressing to status epilepticus in 2 
cases. One patient presented with rapid deteriora- 
tion of mental status, accompanied by vomiting and 
signs of uncal herniation secondary to a massive 
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Fig. 1. TIOS (Treatment and Investigation f Osteosarcoma). Patients were assigned toreceive 7courses (12 weeks) of intra-arterial cis- 
diamminedichloroplatinum-II (CDP) as induction therapy, followed by a surgical procedure. The extent of tumor destruction was assessed. 
Patients responding to the preoperative tr atment (over 60% tumor necrosis) continued treatment with the agent utilized preoperatively 
with the addition of other agents. Alternatively, if tumor destruction was under 60%, the preoperative agent was discarded. The total 
duration of postoperative adjuvant therapy was one year. MTX = High dose methotrexate (12.5 gm/M 2) with citrovorum factor escue 
(15-100 mg q3h IV). ADR = Adriamycin 25 mg/M2/dx3. 
Table 1. Characteristics of patients with osteosarcoma (n= 87). 
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Mean age at diagnosis: 
~ex: 
Follow-up time: 
Survival: 
Patients with pulmonary metastases: 
Time to pulmonary metastases: 
Survival in patients with pulmonary metastases: 
11.8 years (range 1-  16 years) 
Males:Females 40:48 (46%:54%) 
< 1-  6 years (mean 2.4) 
55 alive; 32 dead; 1 unknown 
n=39 
mean = 13, range: diagnosis - 48 months 
12 alive; 27 dead; 1 unknown 
Table 2. Characteristics of patients with osteosarcoma etastatic to brain. 
Patient Agea/Sex Pathology Time to Interval 
pulmonary to brain 
metastasis metastasis 
Presentation Location of 
metastasis 
1 15/M chondroblastic 9 mo 46 mo 
2 
2 l l /F  chondroblastic 45 mo <2 mo 
3 12/M osteoblastic 15 mo 12 mo 
4 8/F osteoblastic 22 mo 17 mo 
5 14/F small cell 1 wk 9 mo 
focal-generalized seizures L parietal, hemorrhagic 
R occipital x 2 
status epilepticus CT unavailable b 
asymptomatic CT unavailable b 
status epilepticus R frontal obe 
rapidly declining mental status L frontal lobe, hemorrhagic 
aAt diagnosis; Uperformed at outside hospitals, exact location of metastases not reported. 
hemorrhage (metastasis verif ied by surgical speci- 
men). The fifth patient was found to have cranial in- 
volvement on routine skeletal survey, and a subse- 
quent CT conf i rmed parenchymal brain 
involvement. In patients 2 and 3 (Table 2) neuroradi-  
ological studies were per formed at an outside hospi- 
tal and informat ion about exact metastasis localiza- 
t ion was unavailable. The gross surgical resection of  
the intracranial  metastases in 2 cases led to clinical 
improvement for several months. The outcome in all 
5 patients, however, has been uni formly fatal. 
Discussion 
The prognosis and survival in osteosarcoma have 
been dismal until the past two decades [1, 2, 6, 10]. 
Despite surgical ext irpation of  the tumor, most pa- 
tients relapsed in lungs, and preterminal ly had dis- 
seminated isease [3 -5 ,  8]. Ma jor  advances have 
been made in the past decade and a half  in eradicat- 
ing the pr imary disease and arresting its dissemina- 
t ion [1, 2, 6, 8]. There are few reports on brain 
metastases from osteosarcoma. Most were reported 
during the prechemotherapy era. Dahl in et al. [5] 
reported 3 cases in an autopsy series of  150 patients. 
More recently, Danzinger et al. [11] presented 3 other 
patients with osteogenic sarcoma metastatic to the 
brain. Each of  these patients had lung metastases be- 
fore discovery of their brain lesions. The cerebral 
metastases were osteo-blastic n 2 of  the 3 cases, di- 
agnosed by skull roentgenography in one and CT in 
the other. The lesions were hypervascular t angiog- 
raphy in 2 cases. One of  the patients presented with 
a focal seizure, the second with progressive hemipa- 
resis, and the third was asymptomatic.  There was no 
informat ion in this report as to the incidence or 
prevalence of  brain metastases from osteogenic sar- 
coma. Giul iano et al. [8] also ment ioned two pa- 
tients with brain metastases among their 111 pa- 
tients, but provided no further details. 
It is unclear whether patients whose pu lmonary  
metastases have been el iminated by surgery or 
chemotherapy remain at a high risk for brain lesions. 
A slow subclinical growth of  a brain metastasis, es- 
tabl ished at the t ime of  presence of  the lung lesion, 
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Fig. 2. Pre (A) and postcontrast (B) scans of patient 1 demon- 
strate a hemorrhagic, enhancing lesion in the left frontoparietal 
region with associated edema. (C) Noncontrast scan of patient 5 
shows a large left frontal hemorrhage with mass effect. At surgery, 
there was an underlying osteosarcoma metastasis. 
or possible persistence of micrometastases in the 
lung may underlie a "late" appearance of a brain le- 
sion on CT. Notwithstanding, it would seem that 
clinical detection of brain metastases (as opposed to 
findings on autopsy) can be attributed to the 
prolonged survival and change in metastatic pat- 
terns induced by chemotherapy [1, 2, 6, 8]. 
The 87 patients in the present report were treated 
with a uniform protocol and had a 45°7o incidence 
of pulmonary metastases. Patients with this compli- 
cation, in turn, had a 13% incidence of brain 
metastases. There was no predilection of any partic- 
ular age or pathological variant of osteosarcoma for 
the development of this complication. The clinical 
presentation has tended to be acute and catastroph- 
ic, necessitating emergency management and ac- 
companied by maj or morbidity. Solitary metastases 
presenting in an otherwise stable individual with 
controlled peripheral disease could be amenable to 
surgical extirpation. Since early detection may avert 
some of the catastrophic omplications of brain 
metastasis, we recommend routine, periodic screen- 
ing (CT or magnetic resonance imaging) of the brain 
be undertaken in osteosarcoma patients with lung 
metastases. 
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Fig. 3. A and B. Precontrast can with brain and bone settings 
in patient 4show a lesion with bone formation a d surrounding 
edema in the right frontal lobe. C. Postcontrast scan reveals mild 
peripheral enhancement. This lesion was surgically verified as os- 
teosarcoma. 
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